Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 18/20 | 0.65 |
| ▸ | SLC5A1 | P13866 | 13/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.63 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20126427 | 1.00 | SLC5A2 (0.65) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL20126426 | 1.00 | SLC5A2 (0.65) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL10083222 | 1.00 | SLC5A2 (0.65) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13259974 | 0.90 | SLC5A2 (0.56) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13259976 | 0.90 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17929392 | 0.87 | SLC5A2 (0.67) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL20126401 | 0.86 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL20126403 | 0.86 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL20126402 | 0.86 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL20126400 | 0.86 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759729-B2 | Compounds for treating diabetes | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2020-09-01 | — | — | US | disclosed |
| US-20180127343-A1 | NOVEL COMPOUNDS FOR TREATING DIABETES | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2018-05-10 | — | — | US | disclosed |
| US-20180127343-A1 | NOVEL COMPOUNDS FOR TREATING DIABETES | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759729-B2 | Compounds for treating diabetes | SLC5A2, GPR119, DPP4 | SLC5A2 1/4885SLC5A1 4/4885ADRA2A 1995/4885 |
| US-20180127343-A1 | NOVEL COMPOUNDS FOR TREATING DIABETES | GPR119, SLC5A2, DPP4 | SLC5A2 2/4885SLC5A1 5/4885ADRA2A 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.